spacer
home > ict > autumn 2016 > a question of standards
PUBLICATIONS
International Clinical Trials

A Question of Standards

In 2013, the International Society for Pharmaceutical Engineering (ISPE) launched a survey to analyse the relationship between patient compliance and packaging (1), in which subjects of clinical trials were asked about their experience when applying investigational medicinal products (IMPs). An overwhelming 77% found their medication easy to use. Since the questionnaire was almost exclusively based on responses by patients from the US, it was expanded in 2015 to include the UK, the EU and Asia. The favourable opinion was, again, confirmed: the majority of participants gave positive feedback regarding the overall ease of application of their IMPs – both in the EU (85%) and in China (88%).

The more user-friendly the labelling of IMPs is, the simpler they are to use. This equation takes centre stage considering the growing demand from subjects for medication to be delivered straight to their homes (75% in the EU; 78% in China; 78% in the US in 2013). In contrast to briefing on the phone – which always means extra work for site personnel – dosing instructions on the package are directly and durably attached to the drug. To be accessible, additional digital information usually requires analogue placeholders on the packaging – such as QR codes – which can only be read by means of technical devices. Having functioning hardware and software is, therefore, a prerequisite.

Just-In-Time Labelling


The labelling of IMPs is subject to demands that are specified in the Good Manufacturing Practice (GMP) Guide within the EU (2), and in the Code of Federal Regulations (CFR) in the US (3). They mostly apply to blister packs or bottles as far as the primary packaging of clinical IMPs is concerned, and to labels on secondary packaging. Label content is governed by EU stipulations in Annex 13 to the Guide, with layout, font size and symbols laid down in the Guideline on Readability (4).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Nurdan Citamak joined Faubel Pharma Services in 2013 and was appointed Director of Business Development and Sales for North America. She graduated in Business Administration from Würzburg-Schweinfurt University, Germany, and majored in International Business at Bond University, Australia. Prior to joining the company, Nurdan spent nearly seven years in New York working in the technology industry.
spacer
Nurdan Citamak
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement